{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:47:17Z","timestamp":1790167637708,"version":"4.1.0"},"reference-count":42,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,8,30]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"\n Background<\/jats:title>\n Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR T) therapy showed remarkable efficacy in patients with relapsed or refractory multiple myeloma (RRMM). This phase 1 dose-escalation and expansion study developed C-CAR088, a novel second-generation humanized anti-BCMA CAR T-cell therapy, and assessed the safety and efficacy of three dosages of C-CAR088 in patients with RRMM.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Patients received lymphodepletion with three doses of cyclophosphamide (300 mg\/m2<\/jats:sup>) and three doses of fludarabine (30 mg\/m2<\/jats:sup>) on days \u20135, \u20134, and \u20133, followed by an infusion of C-CAR088 on day 0. Doses of 1.0\u00d7106<\/jats:sup>, 3.0\u00d7106<\/jats:sup>, and 6.0\u00d7106<\/jats:sup>\u2009CAR T cells\/kg (\u00b120%) were tested in the dose-escalation cohorts and expansion cohorts. The primary endpoint was treatment safety, including the rate of treatment-emergent adverse events after cell infusion. Secondary endpoints were the overall response rate and progression-free survival. The exploratory endpoints were the quantification of C-CAR088 CAR T cells, selection of cytokines and chemokines in blood, and measurement of tumor BCMA expression.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n As of July 2, 2021, 31 patients had been infused with C-CAR088. Any grade cytokine release syndrome (CRS) occurred in 29 patients (93.5%), and grade 3 CRS occurred in 3 patients (9.7%). One patient from the high-dose group (4.5\u20136.0\u00d7106<\/jats:sup>\u2009CAR T cells\/kg) developed grade 1 neurotoxicity. No dose-limiting toxicities were observed in any dose group, and all adverse events were reversible after proper management. The overall response, stringent complete response, complete response (CR), and very good partial response rates were 96.4%, 46.4%, 10.7%, and 32.1%, respectively. The CR rate in the medium-dose (3.0\u00d7106<\/jats:sup>\u2009CAR T cells\/kg) and high-dose (4.5\u20136.0\u00d7106<\/jats:sup>\u2009CAR T cells\/kg) groups was 54.5% and 71.4%, respectively. In the CR group, 15 (93.7%) patients achieved minimal residual disease (MRD) negativity (test sensitivity >1\/10\u22125<\/jats:sup>). All seven patients with double-hit or triple-hit multiple myeloma achieved MRD-negative CR.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The present study demonstrated that C-CAR088 had a good safety profile and high antitumor activity in patients with RRMM, constituting a promising treatment option for RRMM.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n \n NCT03815383<\/jats:ext-link>, NCT03751293<\/jats:ext-link>, NCT04295018<\/jats:ext-link>, and NCT04322292<\/jats:ext-link>.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/jitc-2022-005145","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T11:41:36Z","timestamp":1663069296000},"page":"e005145","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03815383","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03751293","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04295018","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04322292","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-5417","authenticated-orcid":false,"given":"Xiaoyan","family":"Qu","sequence":"first","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Cellular Biomedicine Group Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Huang","sequence":"additional","affiliation":[{"name":"Cellular Biomedicine Group Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Cellular Biomedicine Group Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yao","sequence":"additional","affiliation":[{"name":"Cellular Biomedicine Group Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Cellular Biomedicine Group Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxiao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Cellular Biomedicine Group Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Zhu","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutian","family":"Wei","sequence":"additional","affiliation":[{"name":"Cellular Biomedicine Group Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoteng","family":"Lv","sequence":"additional","affiliation":[{"name":"Cellular Biomedicine Group Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Lan","sequence":"additional","affiliation":[{"name":"Cellular Biomedicine Group Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Yao","sequence":"additional","affiliation":[{"name":"Cellular Biomedicine Group Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihua","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of hematology, Hebei Yanda Lu Daopei Hospital, Langfang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"2025100305375288000_10.9.e005145.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"2025100305375288000_10.9.e005145.2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","article-title":"Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the global burden of disease study 2016","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2025100305375288000_10.9.e005145.3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791"},{"key":"2025100305375288000_10.9.e005145.4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123924","article-title":"Monoclonal antibodies for the treatment of multiple myeloma: an update","volume":"19","author":"Abramson","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025100305375288000_10.9.e005145.5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02431","article-title":"Update on PD-1\/PD-L1 inhibitors in multiple myeloma","volume":"9","author":"Jelinek","year":"2018","journal-title":"Front Immunol"},{"key":"2025100305375288000_10.9.e005145.6","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.5045\/br.2020.S008","article-title":"Treatment of relapsed and refractory multiple myeloma","volume":"55","author":"Lee","year":"2020","journal-title":"Blood Res"},{"key":"2025100305375288000_10.9.e005145.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2011.01067.x"},{"key":"2025100305375288000_10.9.e005145.8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00288"},{"key":"2025100305375288000_10.9.e005145.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903"},{"key":"2025100305375288000_10.9.e005145.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"2025100305375288000_10.9.e005145.11","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T cell therapies for multiple myeloma","volume":"34","author":"Gagelmann","year":"2020","journal-title":"Leukemia"},{"key":"2025100305375288000_10.9.e005145.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025100305375288000_10.9.e005145.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2025100305375288000_10.9.e005145.14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01243","article-title":"Car T-cells in multiple myeloma: state of the art and future directions","volume":"10","author":"Rodr\u00edguez-Lobato","year":"2020","journal-title":"Front Oncol"},{"key":"2025100305375288000_10.9.e005145.15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.13380","article-title":"B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: a meta-analysis","volume":"104","author":"Gagelmann","year":"2020","journal-title":"Eur J Haematol"},{"key":"2025100305375288000_10.9.e005145.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025100305375288000_10.9.e005145.17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk Res"},{"key":"2025100305375288000_10.9.e005145.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-015-9432-2"},{"key":"2025100305375288000_10.9.e005145.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"2025100305375288000_10.9.e005145.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1819745116"},{"key":"2025100305375288000_10.9.e005145.21","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.346","article-title":"A phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"key":"2025100305375288000_10.9.e005145.22","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"2025100305375288000_10.9.e005145.23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"2025100305375288000_10.9.e005145.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"2025100305375288000_10.9.e005145.25","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.5RU0817-315R"},{"key":"2025100305375288000_10.9.e005145.26","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00910-5"},{"key":"2025100305375288000_10.9.e005145.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5"},{"key":"2025100305375288000_10.9.e005145.28","doi-asserted-by":"publisher","DOI":"10.1038\/nature01543"},{"key":"2025100305375288000_10.9.e005145.29","unstructured":"Abecama FDA package insert. Available: https:\/\/www.fda.gov\/media\/147055\/download"},{"key":"2025100305375288000_10.9.e005145.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"2025100305375288000_10.9.e005145.31","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"2025100305375288000_10.9.e005145.32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"key":"2025100305375288000_10.9.e005145.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2031"},{"key":"2025100305375288000_10.9.e005145.34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2020-140156","article-title":"Two-Year follow-up of investigator-initiated phase 1 trials of the safety and efficacy of fully human Anti-Bcma CAR T cells (CT053) in relapsed\/refractory multiple myeloma","volume":"136","author":"Hao","year":"2020","journal-title":"Blood"},{"key":"2025100305375288000_10.9.e005145.35","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ajh.26583","article-title":"Car-T cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status","volume":"97","author":"Du","year":"2022","journal-title":"Am J Hematol"},{"key":"2025100305375288000_10.9.e005145.36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397"},{"key":"2025100305375288000_10.9.e005145.37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"2025100305375288000_10.9.e005145.38","first-page":"260","article-title":"Car T-cell therapy: is it prime time in myeloma?","volume":"3","author":"Sidana","year":"2019","journal-title":"Blood Adv"},{"key":"2025100305375288000_10.9.e005145.39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy152"},{"key":"2025100305375288000_10.9.e005145.40","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T\u00a0Cell Therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"2025100305375288000_10.9.e005145.41","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3"},{"key":"2025100305375288000_10.9.e005145.42","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:38:00Z","timestamp":1759495080000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,13]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/jitc-2022-005145"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005145","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}